DongKoo Bio & Pharm Co. Ltd.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. carries a market capitalization of 101.41B, placing it among publicly traded companies globally. Its enterprise value stands at 173.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. has 27.04M shares outstanding.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. trades at a trailing price-to-earnings ratio of 3.07. The price-to-sales ratio is 0.42, and the price-to-book ratio stands at 0.71.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. trades at an EV/EBITDA multiple of 20.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 511.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. DongKoo Bio & Pharm Co. Ltd. trades at an EV/FCF ratio of 133.56, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 173.50B versus a market cap of 101.41B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. maintains a current ratio of 0.90, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 86.01, indicating elevated leverage, while an interest coverage ratio of 2.26 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, DongKoo Bio & Pharm Co. Ltd. posted a return on equity (ROE) of 25.98, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.11 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.42, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.23, useful for judging operating efficiency across full business cycles. The company generates approximately 555.66M in revenue per employee across its workforce of 434.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.12 indicates how many times DongKoo Bio & Pharm Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, DongKoo Bio & Pharm Co. Ltd. recorded 10.06B in income tax expense. That works out to an effective tax rate of 23.42, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 42.94B, leaving 33.01B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, DongKoo Bio & Pharm Co. Ltd.'s stock has declined approximately 39.78% over the past 52 weeks. The 50-day moving average sits at 3,568.40, while the 200-day moving average is 4,464.28.

Over the twelve months ended June 30, 2026, DongKoo Bio & Pharm Co. Ltd. generated 241.43B in revenue and converted that into 33.01B in net income, yielding earnings per share of 1,207.37. EBITDA reached 8.62B, while operating income came in at 339.04M.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. holds 51.01B in cash and equivalents against 122.63B in total debt, resulting in a net debt position of 102.95B. Total book value stands at 142.11B, with working capital of -13.40B providing operational flexibility.

DongKoo Bio & Pharm Co. Ltd. produced 21.19B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.82B in capital expenditures, free cash flow totaled -1.62B - equivalent to -60.01 per share.

Over the twelve months ended June 30, 2026, DongKoo Bio & Pharm Co. Ltd. posted a gross margin of 57.95, reflecting its pricing power and cost economics. The operating margin of 0.14 and net profit margin of 13.67 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, DongKoo Bio & Pharm Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.81, meaning DongKoo Bio & Pharm Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

DongKoo Bio & Pharm Co. Ltd.'s most recent stock split took place on March 2, 2021 with a 1:3 split ratio.

As of June 30, 2026, DongKoo Bio & Pharm Co. Ltd. has an Altman Z-Score of 1.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.